← All trials
NCT06084364
Phase 4Interventional
Studies of FDA-approved drugs to delineate additional information including the drug's risks, benefits, and optimal use.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Nov 3, 2023
- Primary completion
- Apr 30, 2026
- Completion date
- Nov 30, 2027
- First posted
- Oct 16, 2023
- Last posted
- Nov 8, 2023
- Enrollment
- 354
- Arms / groups
- 3 / —
- Source
- AACT · ctgov ingestion
Sponsors
- Diakonhjemmet HospitalLead sponsor
- Diakonhjemmet HospitalStudy director
- University of StavangerCollaborator
- University of StavangerOverall official - principal investigator
- Martina Hansen's HospitalCollaborator
- Martina Hansen's HospitalOverall official - principal investigator
- Nordland HospitalCollaborator
- Norwegian University of Science and TechnologyCollaborator
- Norwegian University of Science and TechnologyOverall official - principal investigator
- Haugesund HospitalOfficial
- Haugesund HospitalCollaborator
- Diakonhjemmet HospitalOfficial
- Nordland HospitalOfficial
- Norwegian University of Science and TechnologyOfficial
- University of StavangerOfficial
- Martina Hansen's HospitalOfficial
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.